Top Biotechnology Acquirers (2006-2026)

Tracked deals

653

653 tracked deals across 2006-2026.

Buyer mix

Strategic-led

567 strategic · 203 pe

Top trend

Volume peaked in 2022

114 tracked deals announced in 2022.

Primary Insight

What Stands Out

  • Major buyers in this set include AbbVie Inc., Johnson & Johnson, and Novartis, alongside specialized biotech acquirers like Zymeworks Inc. and Tarsus Pharmaceuticals.
  • Deal rationale frequently centers on pipeline growth in areas such as oncology and immunology (e.g., degrader platforms, IL-23 oral therapies, and antibody-based candidates).
  • Platform and technology expansion appears alongside asset acquisitions, including ADC-related payload development and proteomics workflow capability adds.
  • Many agreements structure value around milestones or contingencies—cash upfront plus regulatory/commercial milestones, earn-outs, or CVRs.
  • Deal geography in the recent set includes California (United States), the United Kingdom, Ireland, and Colorado (United States).

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Find buyers like these for your deal

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Biotechnology deal →
Buyer # Deals Focus Type
Ampersand Capital Partners 23 Middle-market private equity firm focused on growth-orien... PE
Eli Lilly and Company 21 Global pharmaceutical company that discovers, develops an... Strategic
AbbVie 7 Global biopharmaceutical company focused on discovery, de... Strategic
ARCHIMED 6 Healthcare-focused private equity firm investing in Europ... PE
Charles River Laboratories International, Inc. 6 Global provider of preclinical and clinical support, labo... Strategic
Novartis 6 Global pharmaceutical company developing and commercializ... Strategic
AstraZeneca 5 Global, science-led biopharmaceutical company focused on ... Strategic
Calibre Scientific 5 Diversified global provider of life‑science reagents, too... Strategic
GHO Capital Partners LLP 5 London-based specialist private equity investor focused o... PE
Gilead Sciences, Inc. 5 Research-based biopharmaceutical company that discovers, ... Strategic

Acquisition Volume in Biotechnology by Year

Last 10 years

Acquisition volume by year Annual acquisition counts for the last 10 years for Top Biotechnology Acquirers (2006-2026). 4 2017 2 2018 29 2019 62 2020 97 2021 114 2022 91 2023 90 2024 83 2025 ~114 est. 68 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • argenx to Acquire Forte Biosciences for $2.2 Billion
    July 27, 2026
    Buyer
    argenx
    Target
    Forte Biosciences, Inc.
    Industry
    Biotechnology
    Location
    Texas, United States
    Type
    Buyout

    argenx and Forte Biosciences announced a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, valuing the deal at approximately $2.2 billion. The transaction is designed to add Forte’s lead anti-CD122 antibody FB102 to argenx’s immunology pipeline and is expected to close in Q3 2026, subject to customary conditions.

  • Scancell Holdings Merges With Neuphoria Therapeutics Under $89 Million Financing Plan
    July 24, 2026
    Buyer
    Scancell Holdings
    Target
    Neuphoria Therapeutics
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    Scancell Holdings and Neuphoria Therapeutics have entered an all-share merger agreement in which Scancell will acquire Neuphoria. The combined company is expected to operate under the Scancell name and list on Nasdaq, alongside Scancell’s existing AIM listing, and finance the transaction with up to $89 million in equity and debt.

  • Eli Lilly Acquires AtaiBeckley in $2.8 Billion Deal
    July 17, 2026
    Buyer
    Eli Lilly and Company
    Target
    AtaiBeckley Inc.
    Industry
    Biotechnology
    Location
    New York, United States
    Type
    Buyout

    Eli Lilly and Company has signed a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical company focused on rapid-acting mental health therapies. The upfront consideration is $6.75 per share in cash (aggregate equity value of about $2.8 billion) plus up to $2.50 per share via contingent value rights tied to development and regulatory milestones.

  • NextCure and Avere Therapeutics Announce Merger and $320 Million Financing to Create Oral IL-23 Biotech
    July 17, 2026
    Buyer
    NextCure, Avere Therapeutics
    Target
    Avere Therapeutics, NextCure
    Industry
    Biotechnology
    Type
    Buyout

    NextCure and Avere Therapeutics have entered into a definitive all-stock merger that will create a publicly traded biotechnology company focused on developing once-weekly oral therapies for inflammatory diseases driven by interleukin-23. The transaction is supported by a concurrent $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group to fund key clinical milestones through Phase 2b and into Phase 3 development.

  • Tarsus Pharmaceuticals Acquires iRenix Medical to Advance IRX-101 for Retina Care
    July 9, 2026
    Buyer
    Tarsus Pharmaceuticals
    Target
    iRenix Medical
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Tarsus Pharmaceuticals announced it has acquired iRenix Medical, adding late-stage investigational ocular antiseptic IRX-101 to its eye care pipeline. Under the agreement, Tarsus will pay about $75 million upfront (cash and stock) and make additional regulatory and commercial milestone payments up to $490 million.

  • Novartis Acquires Myricx Bio (ADC NMTi Payload Platform) for Up to $1.5 Billion
    July 7, 2026
    Buyer
    Novartis
    Target
    Myricx Bio
    Seller
    Sofinnova Partners
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    Sofinnova Partners’ portfolio company Myricx Bio has agreed to be acquired by Novartis in a deal valued at up to $1.5 billion, including $1.1 billion in cash upfront plus potential milestone payments. Myricx Bio is a UK-headquartered biotech developing NMTi payloads and lead ADC assets targeting B7-H3 and HER2 for solid tumors.

  • United Therapeutics Acquires Thymmune Therapeutics
    July 3, 2026
    Buyer
    United Therapeutics
    Target
    Thymmune Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    United Therapeutics announced it has acquired Thymmune Therapeutics, a privately held preclinical-stage biotechnology company developing thymic regenerative cell therapies. The deal includes $140 million paid in cash upfront, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.

  • Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp
    June 29, 2026
    Buyer
    JATT II Acquisition Corp, Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, JATT Ventures II L.P.
    Target
    Talawar Therapeutics, Talawar Tx Inc
    Industry
    Biotechnology
    Location
    New Jersey, United States
    Type
    Buyout

    Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).

  • Boundless Bio and Serapha Bio Announce Merger and $230 Million Private Placement
    June 25, 2026
    Buyer
    Serapha Bio, Boundless Bio
    Target
    Serapha Bio, Boundless Bio
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Boundless Bio and Serapha Bio entered into a definitive agreement to merge in an all-stock transaction. Serapha will combine with Boundless Bio, with the combined company expected to operate as Serapha Bio and trade on Nasdaq under ticker AATD, following a pre-closing $230 million private investment led by RA Capital Management and RTW Investments.

  • AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
    June 22, 2026
    Buyer
    AbbVie
    Target
    Apogee Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    AbbVie entered into a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at approximately $10.9 billion. The boards of both companies have approved the deal, which is expected to close in the third quarter of 2026, subject to customary closing conditions including Apogee shareholder and regulatory approvals.

  • Biogen to Acquire RayThera for Up to $1 Billion
    June 18, 2026
    Buyer
    Biogen Inc.
    Target
    RayThera Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused small-molecule biotech, for up to $1 billion. The deal includes an upfront payment plus milestone payments tied predominantly to future clinical and regulatory achievements, with expected close in the third quarter of 2026.

  • 10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities
    June 10, 2026
    Buyer
    10x Genomics, Inc.
    Target
    Proteintech Genomics (a division within Proteintech Group)
    Seller
    Proteintech Group
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    10x Genomics announced it has acquired Proteintech Genomics, a division within Proteintech Group, to expand its proteomics capabilities for single-cell and spatial multiomics workflows on 10x platforms. The deal adds Proteintech Genomics’ Human Discovery Panel technology and supports 10x’s strategy of integrating transcriptomic and proteomic measurements, including capabilities planned for its Atera platform. Financial terms were not disclosed.

  • Copley Acquisition Corp and Aditxt Agree to Take Ignite Proteomics Public via Business Combination Valuing Company at ~$150 Million
    June 9, 2026
    Buyer
    Copley Acquisition Corp, Ignite Proteomics Holdings (newly formed public holding company)
    Target
    Ignite Proteomics, LLC
    Seller
    Aditxt, Inc.
    Industry
    Biotechnology
    Location
    Colorado, United States
    Type
    Buyout

    Copley Acquisition Corp and Ignite Proteomics (a wholly owned subsidiary of Aditxt) have entered into a definitive business combination agreement to take Ignite public. The transaction values Ignite at an implied equity value of approximately $150 million and is expected to create a newly formed holding company (Ignite Proteomics Holdings) with listings on the NYSE, with Ignite expected to become an independent public company following closing.

  • Johnson & Johnson to Acquire Firefly Bio for $1 Billion
    June 8, 2026
    Buyer
    Johnson & Johnson
    Target
    Firefly Bio, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Johnson & Johnson entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash. The deal is intended to expand Johnson & Johnson’s oncology pipeline using Firefly Bio’s proprietary Firelink degrader antibody conjugate platform, including preclinical candidates for KRAS-driven and other hard-to-treat solid tumors.

  • Incyte Acquires Vega Therapeutics to Expand Hematology Portfolio in Bleeding Disorders
    June 8, 2026
    Buyer
    Incyte
    Target
    Vega Therapeutics
    Seller
    Star Therapeutics, LLC
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront, with up to $750 million in additional milestone payments for total potential consideration of up to $2.0 billion. The deal is intended to add Vega’s Phase 3 monoclonal antibody candidate VGA039 for von Willebrand disease to Incyte’s hematology portfolio.

  • Rallybio Corporation to Acquire Avenzo Therapeutics in $215M Financing Deal
    June 2, 2026
    Buyer
    Rallybio Corporation
    Target
    Avenzo Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Rallybio Corporation entered into a definitive merger agreement to acquire Avenzo Therapeutics, with the combined company expected to operate as Avenzo Therapeutics, Inc. and trade on Nasdaq under the ticker symbol AVZO. The transaction includes a concurrent, oversubscribed $215 million private placement with participation from healthcare institutional investors and mutual funds, and is expected to close in Q4 2026 subject to customary conditions.

  • Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion
    May 27, 2026
    Buyer
    Eli Lilly and Company
    Target
    Vaccine Company, Inc.
    Industry
    Biotechnology
    Location
    Maryland, United States
    Type
    Buyout

    Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

  • Eli Lilly Acquires Engage Biologics
    May 23, 2026
    Buyer
    Eli Lilly and Company
    Target
    Engage Biologics Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.

  • InMed Pharmaceuticals to Merge with Mentari Therapeutics in $290M All-Stock Deal
    May 20, 2026
    Buyer
    InMed Pharmaceuticals, Inc., Fairmount, Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, Vivo Capital, Perceptive Advisors, Sirenia Capital Management LP, Oruka Therapeutics (Oruka Therapeutics executive board involvement)
    Target
    Mentari Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    InMed Pharmaceuticals (NASDAQ: INM) entered into a definitive all-stock merger agreement with privately held Mentari Therapeutics, creating a publicly traded migraine-focused biotech under the Mentari name. The transaction is supported by an oversubscribed $290 million private placement led by Fairmount to fund operations through 2028.

  • Quince Therapeutics Acquires Orphai Therapeutics in Stock-for-Stock Deal and Raises Up to $187M Private Placement
    May 19, 2026
    Buyer
    Quince Therapeutics, Inc.
    Target
    Orphai Therapeutics Inc.
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Quince Therapeutics, Inc. announced it has acquired Orphai Therapeutics Inc. in a stock-for-stock merger, bringing Orphai’s inhaled rapamycin (LAM-001) pulmonary pipeline into Quince. Concurrently, Quince entered into a definitive agreement for a private placement financing raising up to $187 million gross proceeds (including $115 million upfront), expected to fund clinical development milestones through 2028.

  • Zydus Worldwide DMCC to Acquire Assertio Holdings in All-Cash $166.4 Million Tender Offer
    May 13, 2026
    Buyer
    Zydus Worldwide DMCC, Zydus Lifesciences Limited, Zara Merger Sub Inc.
    Target
    Assertio Holdings, Inc.
    Industry
    Biotechnology
    Location
    Illinois, United States
    Type
    Buyout

    Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited, has entered into a definitive agreement to acquire all outstanding shares of Assertio Holdings, Inc. for $23.50 per share in cash, valuing the deal at approximately $166.4 million. The transaction is structured as a tender offer followed by a second-step merger at the same price and is expected to close in the second quarter of 2026 (2026–27 financial year in some reports), subject to customary conditions.

  • Bayer to Acquire Perfuse Therapeutics
    May 7, 2026
    Buyer
    Bayer
    Target
    Perfuse Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Bayer announced an agreement to acquire Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment plus development, regulatory, and commercial milestone payments. The deal is intended to strengthen Bayer’s ophthalmology pipeline by adding PER-001, an investigational therapy in Phase II for glaucoma and diabetic retinopathy.

  • Blackstone Life Sciences Invests $250M in Anagram Therapeutics
    May 7, 2026
    Buyer
    Blackstone Life Sciences
    Target
    Anagram Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Growth capital

    Blackstone Life Sciences (BXLS) announced a $250 million investment in clinical-stage biotech Anagram Therapeutics to advance and commercialize its oral recombinant enzyme replacement therapy, ANG003, for exocrine pancreatic insufficiency (EPI) related to cystic fibrosis and other disorders. The funding is intended to support development through regulatory approval and market launch, including planned mid-stage clinical trials.

  • UCB To Acquire Candid Therapeutics for Up to $2.2 Billion
    May 3, 2026
    Buyer
    UCB
    Target
    Candid Therapeutics
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal includes $2.0 billion in upfront payments and up to $200 million in potential milestone payments, and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance and customary conditions.

  • UCB Acquires Candid Therapeutics
    May 3, 2026
    Buyer
    UCB
    Target
    Candid Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    UCB has agreed to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engagers for autoimmune and inflammatory diseases, for up to $2.2 billion including $2.0 billion upfront. Two River and Vida Ventures, part of the Bellco Health ecosystem, highlighted their roles in founding and early development of Candid following the announced acquisition.

  • XTL Biopharmaceuticals to Acquire Psyga Bio to Build Psychedelic Biotechnology Platform
    April 30, 2026
    Buyer
    XTL Biopharmaceuticals
    Target
    Psyga Bio
    Industry
    Biotechnology
    Location
    Israel
    Type
    Buyout

    XTL Biopharmaceuticals has entered into a definitive share purchase agreement to acquire 100% of Psyga Bio. The deal is structured as a share exchange with no cash consideration at closing, with XTL issuing ADSs representing 40% of Psyga Bio’s issued and outstanding share capital plus milestone-based ADSs up to an additional 10%.

  • Chiesi Group acquires KalVista Pharmaceuticals
    April 29, 2026
    Buyer
    Chiesi Farmaceutici S.p.A., Chiesi Group
    Target
    KalVista Pharmaceuticals, Inc.
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Chiesi Farmaceutici S.p.A./Chiesi Group entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. for approximately $1.5 billion (about $1.9 billion at closing), paying $27.00 per share in cash via a tender offer and subsequent merger. The acquisition was completed on June 11, 2026, with KalVista becoming a wholly owned subsidiary and its stock ceasing to trade on Nasdaq.

  • Profluent and Eli Lilly Partner on AI-Designed Gene Editing Platform Deal (Up to $2.25B+ in Milestones)
    April 28, 2026
    Buyer
    Eli Lilly
    Target
    Profluent
    Industry
    Biotechnology
    Type
    Growth capital

    Air Street Capital portfolio company Profluent announced a multi-program strategic partnership with Eli Lilly to develop AI-designed recombinases for genetic medicine. Profluent will receive an upfront payment, committed R&D funding, and is eligible for up to $2.25 billion in development and commercial milestones, plus tiered royalties on net sales.

  • Ligand Pharmaceuticals to Acquire XOMA Royalty
    April 27, 2026
    Buyer
    Ligand Pharmaceuticals Incorporated
    Target
    XOMA Royalty Corporation
    Seller
    BVF Partners (entities affiliated; via its XOMA holdings)
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire XOMA Royalty Corporation for $39.00 per share in cash, valuing the equity at approximately $739 million. The deal includes a Contingent Value Right (CVR) for XOMA Royalty stockholders tied to a portion of net proceeds from certain pending litigation.

  • Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals
    April 24, 2026
    Buyer
    Telomir Pharmaceuticals, Inc.
    Target
    TELI Pharmaceuticals, Inc.
    Seller
    Certain former TELI shareholders (received milestone-based contributions and Telomir stock)
    Industry
    Biotechnology
    Location
    Florida, United States
    Type
    Buyout

    Telomir Pharmaceuticals completed its previously announced stock-for-stock acquisition of TELI Pharmaceuticals. The deal makes Telomir the sole holder of global rights to Telomir-1 (Telomir-Zn), consolidating worldwide development and commercialization under one structure.

  • Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion
    April 20, 2026
    Buyer
    Eli Lilly and Company, Eli Lilly
    Target
    Kelonia Therapeutics
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Eli Lilly has announced a definitive agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company developing in vivo CAR-T cell therapy via its proprietary gene delivery platform. The deal is valued at up to $7 billion, including a $3.25 billion upfront payment, with additional clinical, regulatory, and commercial milestone payments. Closing is expected in the second half of 2026, subject to customary approvals.

  • Sidewinder Therapeutics Raises $137 Million Series B Financing
    April 15, 2026
    Buyer
    Frazier Life Sciences, Novartis Venture Fund, OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, Alexandria Venture Investments
    Target
    Sidewinder Therapeutics
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Growth capital

    Sidewinder Therapeutics, a biopharmaceutical company developing next-generation bispecific ADCs for cancer, announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund with participation from OrbiMed and new investors including Goldman Sachs Alternatives (Life Sciences), DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and others.

  • Eli Lilly & Company Acquires CrossBridge Bio
    April 14, 2026
    Buyer
    Eli Lilly and Company
    Target
    CrossBridge Bio
    Industry
    Biotechnology
    Location
    Texas, United States
    Type
    Buyout

    Eli Lilly and Company has entered into a definitive agreement to acquire CrossBridge Bio, a Houston-based pre-clinical biotechnology company developing next-generation dual-payload antibody-drug conjugates (ADCs). The deal provides for up to $300 million in total consideration, including upfront and milestone-based payments, to advance CrossBridge Bio’s TROP2-targeting TOP1i/ATRi ADC platform led by CBB-120.

  • Gilead Sciences to Acquire Tubulis (Up to $5.0B) to Expand ADC Oncology Pipeline
    April 7, 2026
    Buyer
    Gilead Sciences
    Target
    Tubulis
    Seller
    EQT Life Sciences (LSP 7 fund)
    Industry
    Biotechnology
    Location
    Germany
    Type
    Buyout

    Gilead Sciences entered into a definitive agreement to acquire Tubulis, a Munich-based clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront in cash plus up to $1.85 billion in contingent milestone payments. Following completion, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation.

  • Anthropic Acquires Coefficient Bio in a $400 Million All-Stock Deal
    April 6, 2026
    Buyer
    Anthropic
    Target
    Coefficient Bio
    Seller
    Dimension
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Anthropic acquired stealth-stage biotech AI startup Coefficient Bio in an all-stock transaction valued at just over $400 million. The Coefficient Bio team (fewer than 10 employees) will be integrated into Anthropic’s healthcare and life sciences division to enhance Claude for Life Sciences for drug discovery and regulatory workflows.

  • Cyclerion Therapeutics and Korsana Biosciences Announce Definitive Merger Agreement
    April 1, 2026
    Buyer
    Korsana Biosciences, Inc.
    Target
    Cyclerion Therapeutics, Inc., Korsana Biosciences, Inc.
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Cyclerion Therapeutics and Korsana Biosciences have entered into a definitive, all-stock merger agreement in which the combined company will operate as Korsana Biosciences, Inc. and trade on Nasdaq under ticker KRSA. An oversubscribed private financing expected to generate gross proceeds of approximately $380 million is expected to close immediately prior to the merger, with the combined company funded through key clinical milestones into 2029.

  • Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 Per Share Plus CVR
    March 31, 2026
    Buyer
    Aurinia Pharmaceuticals Inc., Aurinia Pharma U.S., Inc., Aurinia Merger Sub, Inc.
    Target
    Kezar Life Sciences, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Aurinia Pharmaceuticals has entered into a definitive merger agreement to acquire Kezar Life Sciences in a cash tender offer followed by a merger. Kezar shareholders will receive $6.955 per share in cash plus a non-transferable contingent value right (CVR) tied to potential future milestones and proceeds from Kezar’s legacy assets/collaborations.

  • Eli Lilly Acquires Centessa Pharmaceuticals
    March 31, 2026
    Buyer
    Eli Lilly and Company
    Target
    Centessa Pharmaceuticals plc
    Seller
    a group of shareholders
    Industry
    Biotechnology
    Location
    United Kingdom
    Type
    Buyout

    Eli Lilly and Company entered into a definitive agreement to acquire clinical-stage biopharma Centessa Pharmaceuticals plc for $38.00 per share in cash, plus a non-transferrable contingent value right (CVR) that could bring total consideration to up to $47.00 per share. The deal is structured as a scheme of arrangement under the laws of England and Wales and was expected to close in Q3 2026, subject to shareholder and regulatory approvals and court sanction.

  • Novartis to Acquire Excellergy for up to $2 Billion
    March 27, 2026
    Buyer
    Novartis
    Target
    Excellergy
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Novartis entered into an agreement to acquire Excellergy, a private biotechnology company developing next-generation anti-IgE therapies, in a deal valued at up to $2 billion including upfront and milestone payments. The acquisition will bring Excellergy’s lead asset, Exl-111 (a potentially first-in-class trifunctional effector cell response inhibitor), into Novartis’ allergy and immunology pipeline.

  • Otsuka Pharmaceutical Acquires Transcend Therapeutics
    March 27, 2026
    Buyer
    Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc., Otsuka America Pharmaceutical, Inc.
    Target
    Transcend Therapeutics, Inc.
    Seller
    Transcend shareholders
    Industry
    Biotechnology
    Location
    New York, United States
    Type
    Buyout

    Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.

  • Lunai Bioworks Acquires BBB Delivery Technology and CNS Alzheimer’s Drug Assets from the Clemann Group
    March 26, 2026
    Buyer
    Lunai Bioworks, Inc. (NASDAQ: LNAI)
    Target
    Clemann Group, SAS (or its assignee) — BBB delivery technology and CNS Alzheimer’s drug assets
    Seller
    Clemann Group, SAS
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Lunai Bioworks executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and CNS Alzheimer’s drug assets from the Clemann Group, SAS (or its assignee). The deal is structured as Series B Convertible Preferred with a fixed $1.50 conversion price and is intended to strengthen Lunai’s CNS Alzheimer's pipeline while enabling development across other CNS disorders.

  • Pulmatrix Acquires Eos SENOLYTIX in Definitive Merger
    March 26, 2026
    Buyer
    Pulmatrix, Inc., RCM Eos PIPE HOLDINGS LLC, Rapha Capital Management, LLC
    Target
    Eos SENOLYTIX, Inc.
    Industry
    Biotechnology
    Location
    Texas, United States
    Type
    Buyout

    Pulmatrix, Inc. has entered into a definitive merger agreement to acquire Eos SENOLYTIX, Inc. Upon closing, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker EOSX.

  • Apimeds Pharmaceuticals US Settles With Inscobee and Clears Path to Complete Merger With MindWave Innovations
    March 24, 2026
    Buyer
    Apimeds Pharmaceuticals US, Inc.
    Target
    MindWave Innovations Inc.
    Seller
    Inscobee Inc., Apimeds Inc.
    Industry
    Biotechnology
    Location
    New Jersey, United States
    Type
    Buyout

    Apimeds Pharmaceuticals US, Inc. announced a settlement with Inscobee Inc. and Apimeds Inc. that resolves disputes tied to the previously announced merger with MindWave Innovations Inc. The settlement clears the way to complete the merger transactions and effect the company’s $100 million PIPE financing to support ongoing biotech initiatives, including Lōkahi Therapeutics’ Apitox program.

  • Synsus Private Label Partners Acquires Emerald Bioagriculture
    March 23, 2026
    Buyer
    Synsus Private Label Partners, LLC, Crescentia Capital
    Target
    Emerald Bioagriculture
    Industry
    Biotechnology
    Location
    Montana, United States
    Type
    Buyout

    Synsus Private Label Partners, LLC (Synsus) announced it has acquired Emerald Bioagriculture (Emerald), a biostimulant technologies innovator. The deal is intended to expand Synsus’ technology portfolio and accelerate development and integration of eco-friendly, bio-based inputs for growers, turf managers, and homeowners.

  • MGI Tech Acquires STOmics and CycloneSEQ to Build Integrated Sequencing and Spatial Omics Platform
    March 7, 2026
    Buyer
    MGI Tech
    Target
    STOmics, CycloneSEQ
    Industry
    Biotechnology
    Location
    China
    Type
    Buyout

    MGI Tech announced the acquisition of STOmics and CycloneSEQ to integrate long-read sequencing, short-read sequencing, and spatial omics technologies into a unified platform. The deal brings STOmics’ Stereo-seq spatial multi-omics tech and CycloneSEQ’s nanopore-based long-read sequencing systems in-house, supporting MGI’s “SEQALL+GLI+Omics” strategy and a more comprehensive end-to-end offering for researchers.

  • Solabia Acquires Mibelle Biochemistry, Seqens' Botanical Actives and IVD Activity, and Xebios Group
    March 5, 2026
    Buyer
    Solabia, Astorg, TA Associates
    Target
    Mibelle Biochemistry, Seqens' Botanical Actives and In-Vitro Diagnostics Activity, Xebios Group
    Industry
    Biotechnology
    Location
    France
    Type
    Addon

    Solabia, a Paris-headquartered biotech platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses as part of its international expansion strategy. The acquisitions include Switzerland-based Mibelle Biochemistry, France-based Seqens' Botanical Actives and In-Vitro Diagnostics activity, and Germany/Netherlands-based Xebios Group.

  • Rallybio Corporation Acquires Candid Therapeutics
    March 5, 2026
    Buyer
    Rallybio Corporation
    Target
    Candid Therapeutics, Inc.
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Rallybio Corporation entered into a definitive agreement to acquire clinical-stage biotechnology company Candid Therapeutics in a merger transaction. The combined company will operate as Candid Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol CDRX, with the deal targeted to close in mid-2026 subject to customary conditions and approvals. Concurrently, Candid arranged an oversubscribed private financing of more than $505 million from a syndicate of healthcare institutional investors and mutual funds, expected to fund operations through 2030.

  • Esperion Therapeutics to Acquire Corstasis Therapeutics
    March 5, 2026
    Buyer
    Esperion Therapeutics
    Target
    Corstasis Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Esperion Therapeutics announced it has entered into a definitive agreement to acquire Corstasis Therapeutics for an upfront cash payment of $75 million, with potential milestone payments of up to $180 million. The deal is expected to add Enbumyst (bumetanide nasal spray) to Esperion’s cardiovascular portfolio, leveraging its commercial infrastructure to expand its cardiovascular franchise.

  • Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business
    February 23, 2026
    Buyer
    Axol Bioscience
    Target
    Newcells Biotech (ophthalmology business)
    Seller
    Newcells Biotech
    Industry
    Biotechnology
    Location
    Tyne and Wear, United Kingdom
    Type
    Divestiture

    Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.

  • Sensei Biotherapeutics Acquires Faeth Therapeutics (PIKTOR) and Raises $200 Million in Concurrent Private Placement
    February 18, 2026
    Buyer
    Sensei Biotherapeutics, Inc.
    Target
    Faeth Therapeutics Inc.
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Sensei Biotherapeutics, Inc. announced it acquired Faeth Therapeutics Inc., bringing Faeth’s lead all-oral multi-node oncology asset PIKTOR into Sensei’s pipeline. Concurrently, Sensei entered into a definitive agreement for a $200 million private placement (Series B non-voting convertible preferred stock) with a syndicate of life sciences investors to fund key clinical milestones in endometrial and breast cancer.

Full Export

Purchase this data

Get the full acquisitions list for this page as CSV + XLSX.

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Apply as a Buyer

Frequently Asked Questions

Which big pharma companies appear in these biotechnology acquisitions?

Recent examples include AbbVie Inc., Johnson & Johnson, and Novartis.

What kinds of assets or platforms are being acquired?

The page highlights pipeline assets (including late-stage candidates and preclinical programs) as well as technology/platform additions such as ADC payload platforms, degrader antibody conjugate platforms, and proteomics capability expansion.

Do these biotech deals include milestone payments or contingent consideration?

Yes. Several transactions are structured with cash upfront plus additional regulatory and commercial milestone payments, and some include earn-out payments or contingent value rights (CVRs).

Where is most of the recent activity located?

Recent deal locations include California, United States, with additional locations such as the United Kingdom and Ireland (and other U.S. locations shown include New Jersey and Colorado).

Related Acquisition Pages

Biotechnology Buyers & Acquisitions in Canada Private Equity-Backed Biotechnology Buyers Biotechnology Acquisitions in 2026 Biotechnology Acquisitions in Texas Biotechnology Acquisitions in New York Biotechnology Acquisitions in California Biotechnology Acquisitions in Massachusetts Biotechnology Acquisitions in New Jersey Biotechnology Acquisitions in Colorado